Are Analysts Bullish StemCells Inc (NASDAQ:STEM) After Last Week?

Out of 5 analysts covering StemCells (NASDAQ:STEM), 5 rate it “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. StemCells was the topic in 3 analyst reports since September 2, 2015 according to StockzIntelligence Inc. Below is a list of StemCells Inc (NASDAQ:STEM) latest ratings and price target changes.

30/12/2015 Broker: H.C. Wainwright Rating: Buy Old Target: $2.1 New Target: $1.5 Maintain
24/11/2015 Broker: H.C. Wainwright Rating: Buy New Target: $2.1 Reinitiate

The stock decreased 2.50% or $0.01 on March 4, hitting $0.39. StemCells Inc (NASDAQ:STEM) has declined 4.88% since July 30, 2015 and is downtrending. It has outperformed by 0.27% the S&P500.

StemCells, Inc. is engaged in the research, development, and commercialization of stem cell therapeutics. The company has a market cap of $41.37 million. The Firm is focused on developing and commercializing stem and progenitor cells as the basis for therapeutics and therapies. It currently has negative earnings. The Company’s lead product development program is its CNS Program, in which it is developing applications for HuCNS-SC cells, its human neural platform technology.

The institutional sentiment decreased to 1.9 in 2015 Q3. Its down 0.10, from 2 in 2015Q2. The ratio fall, as 6 funds sold all StemCells Inc shares owned while 4 reduced positions. 8 funds bought stakes while 11 increased positions. They now own 6.81 million shares or 29.01% less from 9.59 million shares in 2015Q2.

Bourgeon Capital Management Llc holds 0.13% of its portfolio in StemCells Inc for 449,620 shares. Sabby Management Llc owns 2.04 million shares or 0.04% of their US portfolio. Moreover, Two Sigma Securities Llc has 0.02% invested in the company for 33,265 shares. The Massachusetts-based New England Private Wealth Advisors Llc has invested 0.01% in the stock. Airain Ltd, a Guernsey-based fund reported 30,578 shares.

StemCells Inc - Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings with’s FREE daily email newsletter.

Add Comment